On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors.

Viral and non-viral vectors for in vivo CAR-T therapy show distinct advantages and limitations, impacting safety, efficacy, and scalability in clinical applications.

• Why it matters: Expanding in vivo CAR-T approaches addresses current challenges like high costs, manufacturing delays, and limited access, crucial for broader cancer treatment options.
• What they did: The review compares viral vectors (lentiviral, adenoviral, adeno-associated viral) and non-viral vectors (LNP, polyplexes, genome-editing tools) across key development factors.
• The result: Findings highlight non-viral vectors' potential for safer, scalable, and cost-effective therapies, paving the way for off-the-shelf CAR-T solutions and improved patient outcomes.